Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,008 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dementias Clear all

Conditions: Drink Too Much, Drinking, Binge, Drunk, Drug Use, Aggression, Aggression Sexual, Peer Group, Safety Issues, Harm Reduction
Interventions: Nightlife Safety Plans (NSP), Fire Safety; Behavioral
Lead sponsor: Pacific Institute for Research and Evaluation; Other
Eligibility: 21 Years and older
Enrollment: 959 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Berkeley, California

Conditions: Polypharmacy, Dementia, Multiple Chronic Conditions, Deprescribing, Mild Cognitive Impairment
Interventions: Educational Materials; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Reading, Pennsylvania

Conditions: Sedentary Behavior, Physical Inactivity, Alzheimer Disease, Protection Against
Interventions: De Pie Intervention, Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD); Behavioral · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 55 Years to 89 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: San Diego, California • Seattle, Washington

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Placebo, Eligard 22.5Mg Suspension for Injection; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 120 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Boca Raton, Florida • New York, New York • Madison, Wisconsin

Conditions: Dementia
Interventions: Resilient Together for Dementia, MEUC; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Anxiety, Depression, Caregiver Burnout, Anxiety Generalized
Interventions: Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community; Other
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Epilepsy
Interventions: Levetiracetam; Drug
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 60 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Telmisartan 20mg, Telmisartan 40mg, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions: TPN-101, 400 mg/day, Placebo; Drug
Lead sponsor: Transposon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: La Jolla, California • Orange, California • San Francisco, California + 5 more

Conditions: Alzheimer's Disease
Interventions: MPC-7869; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 84
States / cities: Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 81 more

Conditions: Lewy Body Disease
Interventions: LBD Biomarker Education and Disclosure; Other
Lead sponsor: Stanford University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sedentary Lifestyle, Stress, Psychological
Interventions: Exergame Experience; Behavioral
Lead sponsor: Brandeis University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: maraviroc (Selzentry); Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Alzheimer Disease
Interventions: Simufilam; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 51 Years to 89 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 107
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more

Conditions: Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions: MemorEM 1000; Device
Lead sponsor: NeuroEM Therapeutics, Inc.; Industry
Eligibility: 63 Years to 84 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: General Anesthesia
Interventions: Propofol, Isoflurane; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer's Disease
Interventions: Placebo, RO5313534; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Orange, California • Torrance, California • Norwalk, Connecticut + 11 more

Conditions: Alzheimer Disease
Interventions: Estrogen; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1999
U.S. locations: 25
States / cities: Birmingham, Alabama • San Diego, California • Jacksonville, Florida + 20 more

Conditions: Alzheimer's Disease
Interventions: donezepil (Aricept); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: New Haven, Connecticut • Albany, New York

Conditions: Alzheimer Disease
Interventions: BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Parkinson's Disease
Interventions: Detailed motor testing, including FoG, in PD subjects; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Alzheimer Disease, White Matter Hyperintensities, Dementia, Aging
Interventions: Florbetaben F18, Transcranial Doppler; Radiation · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 60 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease, Healthy Aging
Interventions: Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease; Device
Lead sponsor: Bright Cloud International Corp; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: North Brunswick, New Jersey

Conditions: Alzheimers Disease
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more

Search by objective public record fields.

Group-based Intervention for Club Patrons

Shared Decision Making About Medication Use for People With Multiple Health Problems

Promoting Physical Activity in Older Hispanic/Latino(a) Adults

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Resilient Together for Dementia (RT-D)

Remember Stuff: A Dyadic-focused Technology to Support Persons With Alzheimer's Disease in the Community

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

Health Evaluation in African Americans Using RAS Therapy

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

Estrogen Hormone Protocol

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

Brain Vascular Disease in Aging and Dementia

Telerehabilitation Alzheimer's Disease Usability (TADU)

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)